Pharma industry returns on R&D investment hit 9-year low

LONDON: The cost of developing a new drug has nearly doubled since 2010 and the world’s 12 biggest drugmakers are making the lowest return on their R&D investments in nine years, according to Deloitte.

An annual survey of the economics of pharma research and development (R&D) by the consultancy found that despite a steady flow of new medicines reaching global markets, the 12 drugmakers’ average return on their R&D fell to 1.9 percent this year, from 3.7 percent a year ago.

The average cost of bringing a new medicine to market is now $2.18 billion, up from $1.19 billion back in 2010.

Yet forecast peak sales for new medicines have halved over the same period to $408 million on average – a decline that reflects a growing focus on relatively small targeted patient groups, leading to multiple niche treatments.

“Despite the launch of many successful products, growing development costs and regulatory constraints are making it more difficult than ever for companies to redeem their R&D investment,” said Deloitte consulting partner Colin Terry.

Overall, R&D returns are down by 8.2 percentage points since 2010, when they stood at 10.1 percent.

A group of younger and more specialised biotech companies analysed by Deloitte fared a lot better, with average returns of 9.3 percent, although this was still down from 12.5 percent in 2017.

The 12 big drugmakers tracked by Deloitte are Pfizer , Roche , Novartis , Sanofi , GlaxoSmithKline , Johnson & Johnson , AstraZeneca , Merck & Co , Eli Lilly , Bristol-Myers Squibb , Takeda and Amgen .

The four biotech companies are Biogen , Celgene , Gilead Sciences and AbbVie .

  • Related Posts

    • Pharma
    • July 8, 2025
    • 17 views
    Indian Medical Association opposes decision to allow homeopaths to prescribe modern medicines post pharma course

    The Indian Medical Association (IMA) on Monday criticised the notification by Maharashtra Medical Council (MMC) that will allow homeopaths to prescribe modern medicines after completing a six-month course in pharmacology.…

    • Pharma
    • July 8, 2025
    • 39 views
    ‘AACI Came, AACI Saw, AACI Conquered’ Indian Accreditation Domain in Healthcare

    As it turns 3, New American Kid on the Block strikes gold Delhi NCR:  AACI (American Accreditation Commission International) took such giant strides in India in just three years as…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Indian Medical Association opposes decision to allow homeopaths to prescribe modern medicines post pharma course

    Indian Medical Association opposes decision to allow homeopaths to prescribe modern medicines post pharma course

    ‘AACI Came, AACI Saw, AACI Conquered’ Indian Accreditation Domain in Healthcare

    ‘AACI Came, AACI Saw, AACI Conquered’ Indian Accreditation Domain in Healthcare

    Traditional medicine crucial to achieving global goals of Universal Health Coverage

    Traditional medicine crucial to achieving global goals of Universal Health Coverage

    Lupin launches Ipratropium Bromide nasal spray in US

    Lupin launches Ipratropium Bromide nasal spray in US